The emergence of drug resistance is the most substantial challenge to the effectiveness of
anticancer therapies. Orthogonal approaches have revealed that a subset of cells, known as …

One of the current stumbling blocks in our fight against cancer is the development of
acquired resistance to therapy, which is attributable to approximately 90% of cancer-related …

Background: Research has demonstrated that some tumor cells can transform into drug-
tolerant persisters (DTPs), which serve as a reservoir for the recurrence of the disease. The …

Phenotypic (ie non-genetic) heterogeneity in melanoma drives dedifferentiation,
recalcitrance to targeted therapy and immunotherapy, and consequent tumor relapse and …

Minimal residual disease (MRD) represents a significant challenge in the treatment of
various cancers, acting as a precursor to relapse and therapeutic resistance. This review …

Many cancer-related deaths including melanoma result from metastases that develop
months or years after the initial cancer therapy. Even the most effective drugs and immune …

The use of chemotherapeutic agents and the development of new cancer therapies over the
past few decades has consequently led to the emergence of myriad therapeutic resistance …

Resistance of BRAF-mutant melanomas to targeted therapy arises from the ability of cells to
enter a persister state, evade treatment with relative dormancy, and repopulate the tumor …

Cellular self-digestion is an evolutionarily conserved process occurring in prokaryotic cells
that enables survival under stressful conditions by recycling essential energy molecules …

Since the discovery of antibiotics, they have served as a potent weapon against bacterial
infections; however, natural evolution has allowed bacteria to adapt and develop coping …